Research programme: antiviral vaccines - Cytos Biotechnology/VECTORIE

Drug Profile

Research programme: antiviral vaccines - Cytos Biotechnology/VECTORIE

Latest Information Update: 13 May 2014

Price : $50

At a glance

  • Originator Cytos Biotechnology
  • Developer Cytos Biotechnology; VECTORIE
  • Class Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Viral infections

Most Recent Events

  • 13 May 2014 Research programme: antiviral vaccines - Cytos Biotechnology/VECTORIE is available for licensing as of 05 May 2014. http://www.cytos.com
  • 18 Aug 2011 Suspended for Viral infections in France (unspecified route)
  • 21 Feb 2011 Early research in Viral infections in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top